177 related articles for article (PubMed ID: 33749379)
1. Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the gray-white matter junction correlates with iron-enriched macrophages.
Mahajan KR; Amin M; Poturalski M; Lee J; Herman D; Zheng Y; Androjna C; Howell M; Fox RJ; Trapp BD; Jones SE; Nakamura K; Ontaneda D
Mult Scler; 2021 Dec; 27(14):2159-2169. PubMed ID: 33749379
[TBL] [Abstract][Full Text] [Related]
2. Cortical hypointensity in T2-weighted gradient-echo sequences in patients with progressive multifocal leukoencephalopathy.
López Sala P; Alberdi Aldasoro N; Zelaya Huerta MV; Bacaicoa Saralegui MC; Cabada Giadás T
Radiologia (Engl Ed); 2020; 62(1):59-66. PubMed ID: 31375267
[TBL] [Abstract][Full Text] [Related]
3. Use of quantitative susceptibility mapping (QSM) in progressive multifocal leukoencephalopathy.
Carra-Dalliere C; Menjot de Champfleur N; Deverdun J; Ayrignac X; Nerrant E; Makinson A; Casanova ML; Labauge P
J Neuroradiol; 2016 Feb; 43(1):6-10. PubMed ID: 26475668
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility-Weighted MR Imaging Hypointense Rim in Progressive Multifocal Leukoencephalopathy: The End Point of Neuroinflammation and a Potential Outcome Predictor.
Thurnher MM; Boban J; Rieger A; Gelpi E
AJNR Am J Neuroradiol; 2019 Jun; 40(6):994-1000. PubMed ID: 31122919
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide-associated progressive multifocal leukoencephalopathy in multiple myeloma: cortical susceptibility-weighted imaging hypointense findings prior to clinical deterioration.
Ueno H; Kikumto M; Takebayashi Y; Ishibashi H; Takahashi T; Yasutomi H; Umemoto K; Nakamichi K; Saijo M; Ichinohe T; Maruyama H
J Neurovirol; 2020 Jun; 26(3):452-455. PubMed ID: 32394398
[TBL] [Abstract][Full Text] [Related]
6. Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
Alleg M; Solis M; Baloglu S; Cotton F; Kerschen P; Bourre B; Ahle G; Pruvo JP; Leclerc X; Vermersch P; Papeix C; Maillart É; Houillier C; Chabrot CM; Claise B; Malak S; Martin-Blondel G; Bonneville F; Caulier A; Marolleau JP; Bonnefoy JT; Agape P; Kennel C; Roussel X; Chauchet A; De Seze J; Fafi-Kremer S; Kremer S
Eur Radiol; 2021 May; 31(5):2944-2955. PubMed ID: 33155106
[TBL] [Abstract][Full Text] [Related]
7. Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study.
Pontillo G; Cocozza S; Lanzillo R; Borrelli P; De Rosa A; Brescia Morra V; Tedeschi E; Palma G
Front Neurol; 2017; 8():294. PubMed ID: 28674518
[TBL] [Abstract][Full Text] [Related]
8. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain.
Ono D; Shishido-Hara Y; Mizutani S; Mori Y; Ichinose K; Watanabe M; Tanizawa T; Yokota T; Uchihara T; Fujigasaki H
Neuropathology; 2019 Aug; 39(4):294-306. PubMed ID: 31155757
[TBL] [Abstract][Full Text] [Related]
9. MRI pattern in asymptomatic natalizumab-associated PML.
Wattjes MP; Vennegoor A; Steenwijk MD; de Vos M; Killestein J; van Oosten BW; Mostert J; Siepman DA; Moll W; van Golde AE; Frequin ST; Richert ND; Barkhof F
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):793-8. PubMed ID: 25205744
[TBL] [Abstract][Full Text] [Related]
10. An autopsy case of progressive multifocal leukoencephalopathy with massive iron deposition in juxtacortical lesions.
Okamoto K; Takeda A; Hatsuta H; Sano T; Takao M; Ohsawa M; Miki Y; Nakamichi K; Itoh Y
Neuropathology; 2023 Oct; 43(5):396-402. PubMed ID: 36847459
[TBL] [Abstract][Full Text] [Related]
11. Low signal intensity in U-fiber identified by susceptibility-weighted imaging in two cases of progressive multifocal leukoencephalopathy.
Miyagawa M; Maeda M; Umino M; Kagawa K; Nakamichi K; Sakuma H; Tomimoto H
J Neurol Sci; 2014 Sep; 344(1-2):198-202. PubMed ID: 24972818
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Hodel J; Bapst B; Outteryck O; Verclytte S; Deramecourt V; Benadjaoud MA; Pruvo JP; Vermersch P; Leclerc X
Mult Scler; 2018 Dec; 24(14):1902-1908. PubMed ID: 29343163
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
[TBL] [Abstract][Full Text] [Related]
14. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance.
Wijburg MT; Witte BI; Vennegoor A; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Uitdehaag BM; Barkhof F; Killestein J; Wattjes MP
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1138-45. PubMed ID: 27530808
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
Wattjes MP; Barkhof F
Curr Opin Neurol; 2014 Jun; 27(3):260-70. PubMed ID: 24739400
[TBL] [Abstract][Full Text] [Related]
16. Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Hodel J; Darchis C; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Zins M; Pruvo JP; Vermersch P; Leclerc X
Neurology; 2016 Apr; 86(16):1516-23. PubMed ID: 27009257
[TBL] [Abstract][Full Text] [Related]
17. Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.
Hodel J; Outteryck O; Verclytte S; Deramecourt V; Lacour A; Pruvo JP; Vermersch P; Leclerc X
AJNR Am J Neuroradiol; 2015 Dec; 36(12):2296-302. PubMed ID: 26316568
[TBL] [Abstract][Full Text] [Related]
18. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
19. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
